[1]王子宜,许明岩,王丽媛,等.芪甲软肝丸治疗肝硬化代偿期疗效研究[J].陕西中医杂志,2024,(4):507-510.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.016]
　WANG Ziyi,XU Mingyan,WANG Liyuan,et al.Effect of Qijia Ruangan pill in the treatment of compensatory stage of liver cirrhosis[J].,2024,(4):507-510.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.016]
点击复制

芪甲软肝丸治疗肝硬化代偿期疗效研究
分享到：

《陕西中医》杂志[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年4期
页码:
507-510
栏目:
临床研究
出版日期:
2024-04-05

文章信息/Info

Title:
Effect of Qijia Ruangan pill in the treatment of compensatory stage of liver cirrhosis
作者:
王子宜; 许明岩; 王丽媛; 孔庆辉
(山东中医药大学附属威海市中医院肝病科,山东 威海 264200)
Author(s):
WANG Ziyi; XU Mingyan; WANG Liyuan; KONG Qinghui
(Department of Hepatology,Weihai Hospital of Traditional Chinese Medicine,Shandong University of Traditional Chinese Medicine,Weihai 264200,China)
关键词:
肝硬化;  代偿期;  芪甲软肝丸;  安络化纤丸;  瞬时弹性检测;  肝功能
Keywords:
Liver cirrhosis;  Compensatory stage;  Qijia Ruangan pill;  Anluo Huaxian pill;  Fibroscan;  Liver function
分类号:
R 575.2
DOI:
DOI:10.3969/j.issn.1000-7369.2024.04.016
文献标志码:
A
摘要:
目的:评价芪甲软肝丸治疗肝硬化代偿期的临床疗效。方法:选取肝硬化代偿期患者100例,随机分为观察组50例、对照组50例。在常规治疗基础上,观察组加用芪甲软肝丸口服,对照组加用安络化纤丸口服,两组均治疗3个月。分别于治疗前后检测Fibroscan弹性值、脾长度、脾厚度、门静脉主干内径、脾静脉内径; 检测谷草转氨酶(AST)、谷丙转氨酶(ALT)、总胆红素(TBIL)水平,评价中医症候积分及综合疗效。结果:观察组总有效率优于对照组(P<0.05)。治疗后观察组中医症候积分低于对照组(P<0.05)。治疗后观察组及对照组Fibroscan弹性值较治疗前降低,且观察组低于对照组(P<0.05)。治疗后观察组肝功能指标AST、TBIL、ALT较治疗前降低(均P<0.05),其中AST改善程度优于对照组(均P<0.05)。治疗后观察组肝脾超声门静脉内径、脾静脉内径、脾脏厚度、脾脏长度较治疗前降低(均P<0.05),且观察组门静脉内径数值改善程度优于对照组(均P<0.05)。结论:芪甲软肝丸能有效改善肝硬化代偿期患者肝功能、缓解临床症状、延缓肝硬化进程,且未见明显不良反应。
Abstract:
Objective:To evaluate the clinical efficacy of Qijia Ruangan pill in the treatment of compensated stage of liver cirrhosis.Methods:100 patients were randomly divided into 50 cases in the observation group and 50 cases in the control group.On the basis of conventional treatment,the observation group was orally administered with the traditional Chinese medicine Qijia Ruangan pill,and the control group was orally administered with Anluo Huaxian pill,and both groups were treated for 3 months.Fibroscan elasticity value,spleen length,spleen thickness,portal vein trunk internal diameter,splenic vein internal diameter,albumin transaminase(AST),alanine transaminase(ALT),total bilirubin(TBIL)were measured before and after the treatment.And the Chinese medicine symptom scores and the comprehensive therapeutic efficacy were evaluated,respectively.Results:The efficacy of the observation group was significantly better than that of the control group(P<0.05).After treatment,the scores of TCM symptoms in the observation group was lower than that in the control group(P<0.05).The Fibroscan elasticity of the observation group and the control group after treatment was significantly lower than that before treatment,and the observation group was lower than the control group(all P<0.05).After treatment,the liver function indexes AST,TBIL and ALT in the observation group were significantly lower than those before treatment(all P<0.05),and the improvement degree of AST was significantly better than that of the control group(P<0.05).After treatment,the portal vein diameter,splenic vein diameter,spleen thickness and spleen length in the observation group were significantly decreased compared with those before treatment(all P<0.05),and the improvement of portal vein diameter in the observation group was significantly better than that in the control group(P<0.05).Conclusion:Qijia Ruangan pill can effectively improve the liver function of patients with cirrhosis in the compensatory stage,relieve clinical symptoms,and delay the process of cirrhosis,with significant clinical efficacy and no obvious adverse reactions.

参考文献/References:

[1] 王妮娜.乙肝后肝硬化中医证型与肝纤维化指标的相关性研究[D].南京:南京中医药大学,2009.
[2] 陈毅然,张文富.基于分段论治理论治疗肝硬化腹水研究进展[J].陕西中医,2023,44(10):1487-1490.
[3] 刘翔宇,王凌云.环杷明抑制肝星形细胞激活改善肝纤维化作用实验研究[J].陕西医学杂志,2020,49(6):663-666.
[4] 李娟,曹平虎,唐先梅,等.双环醇片联合恩替卡韦治疗慢性乙型肝炎疗效及对患者肝功能的保护作用[J].陕西医学杂志,2021,50(10):1271-1274.
[5] 陈炎生,费新应,刘立涛,等.膈下逐瘀汤联合拉米夫定治疗乙型肝炎肝硬化疗效观察[J].湖北中医杂志,2012,34(7):5-6.
[6] 刘雪,邓厚波,于杰,等.加味膈下逐瘀汤治疗乙肝肝硬化代偿期的临床观察[J].世界最新医学信息文摘,2015,15(95):32-33.
[7] 刘成海,危北海,姚树坤.肝硬化中西医结合诊疗共识[J].中国中西医结合消化杂志,2011,19(4):277-279.
[8] 中华人民共和国卫生部.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002:143-155.
[9] 苟艳子,梁振斌.中医综合治疗代偿期肝硬化40例临床观察[J].中医临床研究,2016,6:71-72.
[10] 宋国新,韦志强.肝水的中药成方治疗窥探[J].北方药学,2013(7):35.
[11] 于侑新,铁生花,陈四清,等.乙肝肝硬化失代偿期证治探讨[J].中医临床研究,2023,15(28):122-125.
[12] 杨震.论肝主敷和[J].陕西中医,2022,43(10):1323-1325.
[13] 盛国光,朱清静,徐建良,等.肝炎肝硬化失代偿期患者中医证型临床特点分析[J].中西医结合肝病杂志,2007(1):38-40.
[14] 王靖思,陈兰羽,刘玉琴,等.孙桂芝从补脾胃、治未病论治肝癌经验[J].中医杂志,2015,56(13):1096-1098.
[15] 汪德清,沈文梅,田亚平,等.黄芪的三种提取成分对氧自由基作用的影响[J].中国药理学通报,1994(2):129-132.
[16] 陈琪,何祥玉,周曼佳,等.白芍的化学成分、药理作用和临床应用研究进展[J].临床医学研究与实践,2021,6(11):187-189.
[17] 都广礼.疏肝利胆法对免疫性肝纤维化大鼠细胞外基质代谢与免疫调控机制的研究[D].沈阳:辽宁中医学院,2002.
[18] JIN C,ZHANG P J,BAO C Q,et al.Protective effects of atractylodes macrocephala polysaccharide on liver ischemia-reperf fusion injury and its possible mechanism in rats[J].Am J Chin Med,2011,39(3):489-502.
[19] 樊佳,刘晓谦,彭博,等.中药鸡内金的现代研究进展[J].世界中医药,2021,16(17):2542-2547.
[20] 孙兰,刘世成,胡小鹰.三七保肝作用及其机理研究进展[J].中医药信息,2006(1):17-19.
[21] 胡春玲,彭小芝,唐尹萍,等.鳖甲水解多肽的纯化、鉴定及体外抗肝纤维化活性研究[J].中国药学,2017,26(8):605-610.
[22] 梁瀞云,唐燕,司马玲,等.柴胡疏肝散在肝脏疾病中的应用研究进展[J].陕西中医,2022,43(11):1651-1653.
[23] 王飞.五味子保肝作用物质基础[J].人人健康,2018,469(8):229.
[24] 沈利霞,苏贤凤.甘草酸对感染人巨细胞病毒的人胚肺成纤维细胞凋亡和炎性反应的影响[J].实用临床医药杂志,2023,27(1):38-43.
[25] 周晓丽,施文娟,张妍,等.FibroScan对ALT2×ULN慢性乙型肝炎患者肝纤维化程度的诊断价值[J].甘肃医药,2023,42(7):628-629,642.

相似文献/References:

[1]傅琪琳,唐颖慧,黄 甫,等.理饮汤治疗肝硬化失代偿期并发肝性胸水疗效研究[J].陕西中医杂志,2019,(6):733.
　FU Qilin,TANG Yinghui,HUANG Fu,et al.Effecte of Liyin decoction adjuvant treatment in decompensated cirrhosis with hepatic pleural effusion[J].,2019,(4):733.
[2]田莉婷,刘雪萍,李丹妮,等.加味苓桂术甘汤对脾肾阳虚型肝硬化失代偿期患者生存率的影响*[J].陕西中医杂志,2019,(10):1373.
　TIAN Liting,LIU Xueping,LI Danni,et al.Effect of Jiawei Lingui Shugan decoction on survival rate of patients with spleen，kidney and Yang deficiency type decompensated cirrhosis[J].,2019,(4):1373.
[3]聂姝常,王妙苗,程彬彬.肝硬化合并肠道功能失调的中西医结合治疗研究进展[J].陕西中医杂志,2023,(2):259.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.028]
　NIE Shuchang,WANG Miaomiao,CHENG Binbin.Research progress of traditional Chinese and western medicine for treating intestinal dysfunction in liver cirrhosis[J].,2023,(4):259.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.028]

备注/Memo

备注/Memo:
基金项目:山东省中医药科技项目(Q-2023118); 山东省中医药科技发展计划项目(2015-451)
更新日期/Last Update: 2024-04-10